NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free ALLO Stock Alerts $4.47 +0.01 (+0.22%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.41▼$4.5850-Day Range$3.09▼$5.6352-Week Range$2.23▼$6.89Volume1.38 million shsAverage Volume2.80 million shsMarket Capitalization$755.83 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Allogene Therapeutics alerts: Email Address Allogene Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside194.6% Upside$13.17 Price TargetShort InterestBearish26.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingAcquiring Shares$684 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector513th out of 938 stocksBiological Products, Except Diagnostic Industry85th out of 154 stocks 4.4 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.17, Allogene Therapeutics has a forecasted upside of 194.6% from its current price of $4.47.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted26.58% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 10.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 1.3 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $684.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.40% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to remain at ($1.72) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Allogene Therapeutics Stock (NASDAQ:ALLO)Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Read More ALLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLO Stock News HeadlinesMarch 20, 2024 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Given Buy Rating at HC WainwrightMarch 20, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 19, 2024 | markets.businessinsider.comAllogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic AdvancementsMarch 19, 2024 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by Royal Bank of CanadaMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)March 16, 2024 | finance.yahoo.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finanznachrichten.deAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 15, 2024 | markets.businessinsider.comAllogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel TherapyMarch 15, 2024 | markets.businessinsider.comAllogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value GrowthMarch 14, 2024 | investorplace.comALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023March 14, 2024 | msn.comAllogene Therapeutics files for $500M mixed shelfMarch 14, 2024 | globenewswire.comAllogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateMarch 13, 2024 | msn.comAllogene Therapeutics Q4 2023 Earnings PreviewMarch 13, 2024 | finance.yahoo.comZinc Polycarboxylate Cement Market Size is Anticipated to Reach USD 282.1 million by 2031, with a CAGR of 5.6%. - Transparency Market Research, Inc.March 12, 2024 | markets.businessinsider.comAllogene, Arbor Announce Global Gene Editing Licensing Agreement For CAR T PlatformMarch 12, 2024 | globenewswire.comAllogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseMarch 6, 2024 | finanznachrichten.deANTION BIOSCIENCES SA: Antion Biosciences announces latest data and validation of its technology platform through important milestone achievementsMarch 5, 2024 | globenewswire.comAllogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateFebruary 28, 2024 | globenewswire.comAllogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceFebruary 25, 2024 | ca.finance.yahoo.comALGS Apr 2024 2.500 callFebruary 16, 2024 | finance.yahoo.comAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaFebruary 16, 2024 | globenewswire.comAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaJanuary 30, 2024 | uk.investing.comAllogene Therapeutics Inc (ALLO)January 23, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsightJanuary 19, 2024 | realmoney.thestreet.comAllogene Therapeutics price target lowered by $2 at H.C. Wainwright, here's whySee More Headlines Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2023Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees359Year Founded2018Price Target and Rating Average Stock Price Target$13.17 High Stock Price Target$28.00 Low Stock Price Target$7.00 Potential Upside/Downside+194.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-327,270,000.00 Net Margins-202,366.25% Pretax Margin-344,489.50% Return on Equity-53.76% Return on Assets-43.24% Debt Debt-to-Equity RatioN/A Current Ratio12.38 Quick Ratio12.38 Sales & Book Value Annual Sales$90,000.00 Price / Sales8,398.14 Cash FlowN/A Price / Cash FlowN/A Book Value$3.04 per share Price / Book1.47Miscellaneous Outstanding Shares169,090,000Free Float122,761,000Market Cap$755.83 million OptionableOptionable Beta0.81 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 75)M.D., Co-Founder & Executive Chairman Comp: $714.25kDr. David D. Chang M.D. (Age 64)Ph.D., Co-Founder, President, CEO & Director Comp: $1.1MMr. Joshua A. Kazam (Age 47)Co-Founder & Director Comp: $711kMr. Geoffrey M. Parker (Age 60)Executive VP & CFO Mr. Timothy L. Moore Ph.D. (Age 63)Executive VP & Chief Technical Officer Mr. Earl M. Douglas Esq. (Age 61)General Counsel & Compliance Officer Ms. Susan R. Lundeen (Age 58)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy OfficerDr. Zachary J. Roberts M.D. (Age 46)Ph.D., Executive VP of Research & Development and Chief Medical Officer Yinlin ChenSenior Vice President of FinanceMore ExecutivesKey CompetitorsCullinan OncologyNASDAQ:CGEMExscientiaNASDAQ:EXAIFate TherapeuticsNASDAQ:FATEHilleVaxNASDAQ:HLVXNovavaxNASDAQ:NVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 1,556,979 shares on 3/11/2024Ownership: 5.367%Goldman Sachs Group Inc.Bought 1,929,258 shares on 3/1/2024Ownership: 1.983%American International Group Inc.Bought 5,955 shares on 2/28/2024Ownership: 0.028%Price T Rowe Associates Inc. MDSold 35,875 shares on 2/16/2024Ownership: 1.409%GSA Capital Partners LLPSold 106,294 shares on 2/16/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ALLO Stock Analysis - Frequently Asked Questions Should I buy or sell Allogene Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks. What is Allogene Therapeutics' stock price target for 2024? 8 Wall Street research analysts have issued 12 month price targets for Allogene Therapeutics' shares. Their ALLO share price targets range from $7.00 to $28.00. On average, they anticipate the company's stock price to reach $13.17 in the next twelve months. This suggests a possible upside of 194.6% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts. How have ALLO shares performed in 2024? Allogene Therapeutics' stock was trading at $3.21 at the start of the year. Since then, ALLO shares have increased by 39.3% and is now trading at $4.47. View the best growth stocks for 2024 here. Are investors shorting Allogene Therapeutics? Allogene Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 27,750,000 shares, an increase of 11.0% from the February 29th total of 25,010,000 shares. Based on an average daily trading volume, of 2,780,000 shares, the days-to-cover ratio is presently 10.0 days. Approximately 26.6% of the company's stock are short sold. View Allogene Therapeutics' Short Interest. When is Allogene Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ALLO earnings forecast. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.01 million. Allogene Therapeutics had a negative trailing twelve-month return on equity of 53.76% and a negative net margin of 202,366.25%. Allogene Therapeutics's revenue was down 48.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.52) earnings per share. What ETFs hold Allogene Therapeutics' stock? ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX) and What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.37%), Vanguard Group Inc. (5.37%), Primecap Management Co. CA (3.14%), Goldman Sachs Group Inc. (1.98%), Goldman Sachs Group Inc. (1.98%) and Price T Rowe Associates Inc. MD (1.41%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Geoffrey M Parker, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.